

1 **CIITA G-286A promoter polymorphism impairs monocytes HLA-DR expression in**  
2 **septic shock and is rescued by interferon- $\gamma$**

3

4 Jordi Miatello<sup>1,2</sup>, Anne-Claire Lukaszewicz<sup>3,4</sup>, Valérie Faivre<sup>5,6</sup>, Stéphane Hua<sup>7</sup>, Kim Zita  
5 Martinet<sup>7</sup>, Christine Bourgeois<sup>7</sup>, Lluís Quintana-Murci<sup>8,9</sup>, Didier Payen<sup>10</sup>, Michele  
6 Boniotto<sup>11\*</sup>, Pierre Tissières<sup>1,2\*</sup>

7

8 <sup>1</sup>Institute of Integrative Biology of the Cell, CNRS, CEA, Paris-Saclay University, Gif-sur-  
9 Yvette, France;

10 <sup>2</sup>Paediatric Intensive Care and Neonatal Medicine, AP-HP, of Paris-Saclay University,  
11 Bicêtre Hospital, Le Kremlin-Bicêtre, France;

12 <sup>3</sup>EA 7426 PI3 (Pathophysiology of Injury-induced Immunosuppression), Hospices Civils de  
13 Lyon/ Lyon University/bioMérieux, E. Herriot Hospital, Lyon, France;

14 <sup>4</sup>Department of Anesthesiology and Intensive Care, Hospices Civils de Lyon, Neurological  
15 Hospital Pierre Wertheimer, Lyon University, Bron, France;

16 <sup>5</sup>Saint-Louis Lariboisière Hospital, AP-HP, Denis Diderot University, Paris, France;

17 <sup>6</sup>INSERM 1160 Denis Diderot University, Paris, France;

18 <sup>7</sup>Paris-Saclay University, INSERM, CEA, Center for Immunology of Viral, Auto-immune,  
19 Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses, France;

20 <sup>8</sup>Unit of Human Evolutionary Genetics, CNRS, UMR2000, Institut Pasteur, Paris, France;

21 <sup>9</sup>Chair Human Genomics and Evolution, Collège de France, Paris, France;

22 <sup>10</sup>Denis Diderot University, Paris, Sorbonne, Cité Paris, France;

23 <sup>11</sup>Institut Mondor for Biomedical Research/INSERM U955 Team 16, Paris-Est Créteil  
24 University, Créteil, France.

25 \* Both authors contributed equally.

1    **Corresponding authors:**    Pierre Tissières, MD, DSc  
2  
3                                    Institute of Integrative Biology of the Cell  
4                                    CNRS, CEA, Paris Saclay University  
5                                    1 Avenue de la Terrasse  
6                                    91190 Gif-sur-Yvette, France  
7                                    Email : pierre.tissieres@i2bc.paris-saclay.fr

8    **Statement of equal author contributions:** MB and PT contributed equally.

9  
10   **Statement of article series:** none.

11  
12   **Statement of prior presentation:** presented partially in abstract form at the Cell symposia:  
13   Human immunity, Lisbon, Portugal, August 2012.

14  
15   **Manuscript word count:** 4277 words

1 **Keypoints**

- 2 • CIITA G-286A polymorphism reduces promotor activity and significantly impact  
3 monocyte HLA-DR expression and mortality in septic shock
- 4 • Downregulatory effects of CIITA G-286A polymorphism on monocyte HLA-DR  
5 expression can be reverse by IFN- $\gamma$  in patients with septic shock

6

7 **ABSTRACT (245 words)**

8 Monocyte HLA-DR is an increasingly recognized markers of sepsis-induced  
9 immunodepression, but its regulatory mechanisms remain poorly understood in sepsis.  
10 Several evidence for positive selection on the 5' promoter region of HLA class II  
11 transactivator (*CIITA*) gene, the master regulator of MHC class II, have been gathered in the  
12 European population, and its role in sepsis has never been demonstrated, whilst suggested in  
13 autoimmune disease. We aim to describe the effect of rs3087456 polymorphism, localized on  
14 *CIITA* promoter III (pIII), on mortality of patients with septic shock, and investigate the  
15 mechanisms regulating HLA-DR expression. Genotyping of 203 patients with septic shock  
16 showed that, in A dominant model, GG genotype was associated with 28-day mortality (OR  
17 2.29; 95%CI: 1.01 to 5.22;  $P = 0.043$ ). Monocyte HLA-DR remained low in patients with GG  
18 genotype whereas it increases as early as at the end of the first week in intensive care in  
19 patients with AA or AG genotype. Using site-directed mutagenesis, *in vitro* reporter gene  
20 promoter activity of the pIII was decreased in GG genotype in monocyte cell line. Interferon- $\gamma$   
21 (IFN- $\gamma$ ) restored pIII activity in GG genotype as well as restore, in *ex vivo* experiment in  
22 healthy volunteers, *CIITA* pIII expression of GG genotype. Hereby, we demonstrated that  
23 rs3087456, a positively selected polymorphism of *CIITA* proximal promoter, significantly  
24 impact monocyte HLA-DR expression in patients with septic shock through *CIITA* promoter

- 1 activity, that can be rescued using IFN- $\gamma$ , offering a new perspective in genetic susceptibility
- 2 to sepsis and targeted immunomodulatory therapy.

## 1 INTRODUCTION

2 Sepsis is a life-threatening condition with more than 19 million cases and 5 million deaths per  
3 year worldwide and is recognized as a global priority by the World Health Organization <sup>1,2</sup>.  
4 Incidence of sepsis has increased during last decades because of advancing age,  
5 immunodepression and multidrug-resistant infections <sup>3</sup>. Nevertheless, mortality remains stable  
6 pending the prompt administration of antibiotics, the use of fluid resuscitation and  
7 vasopressors to reverse hypotension and maintain tissue perfusion <sup>4</sup>. Sepsis is now widely  
8 recognized as an inappropriate host response to infection with transient or persistent state of  
9 immunodepression <sup>5,6</sup>. Diagnosis and specific therapies targeting host response, such as anti-  
10 endotoxin serum or purified anti-endotoxin <sup>7</sup>, high-dose steroids or inhibitors of the pro-  
11 inflammatory cytokines IL-1, IL-1 receptor, and TNF- $\alpha$  <sup>8-10</sup>, anticoagulants <sup>11,12</sup> (activated  
12 protein C) were investigated. Beside strong physiopathologic rationale, most of these studies  
13 failed to be beneficial. However, when patients are stratified according to specific  
14 immunological phenotypes, these therapies were shown to improve survival, whilst worsening  
15 the conditions of others <sup>13</sup>.  
16 Sepsis-induced immunodepression is now recognized as being associated with both mortality  
17 and emergence of secondary infections <sup>14,15</sup>. To assess the patients' immunodepression status,  
18 use of HLA-DR expression in circulating monocytes (mHLA-DR) is widely recognized <sup>16</sup>. A  
19 persistent low level of mHLA-DR measured by flow cytometry is associated with the  
20 development of secondary infections and impaired clinical outcome <sup>14,15</sup>. Similarly, decreased  
21 mRNA levels of several genes controlling HLA-DR protein structure, transport and peptide  
22 loading have been associated to poor sepsis outcome <sup>17-19</sup>. Among these, expression of the  
23 master regulator of HLA class II, class II transactivator (*CIITA*), was shown to be reduced in  
24 deceased septic patients <sup>17</sup>. MHC class II expression is controlled at the level of transcription  
25 by a highly conserved regulatory module that is found in the promoters of the gene encoding

1 the  $\alpha$ -chain and  $\beta$ -chain of all MHC class II molecules (HLA-DP, -DQ, -DR, HLA-DM and -  
2 DO). *CIITA* gene expression is regulated mainly at the level of transcription that is driven by  
3 a large regulatory region containing four distinct promoters. Among these four promoters  
4 regions, three main *CIITA* isoforms are produced but their functions are not clear yet. Cell  
5 specificity is determined by transcriptional control of the *CIITA* gene through the differential  
6 activity of three of the four promoter regions. Promoter I (pI) is used mainly in dendritic cells  
7 and is - induced IFN- $\gamma$  in macrophages, pIII is activated in B cells and activated T cells, and  
8 pIV is induced by IFN- $\gamma$  in cells that do not express usually the MHC class II <sup>20</sup>.

9 Mutations of *CIITA* gene are causing severe haplotype insufficiency, such in bare  
10 lymphocytes syndrome, that impairs expression of MHC class II genes <sup>21,22</sup>. Among the  
11 various single nucleotide polymorphism (SNP) described, rs3087456 in the *CIITA* pIII is  
12 associated to a variety of immune-inflammatory disease and cancer <sup>23,24</sup>. Swanberg et al <sup>23</sup>  
13 showed that rs3087456 influence *CIITA* and HLA-DR transcripts in human peripheral blood  
14 mononuclear cells (PBMCs) stimulated by IFN- $\gamma$  and demonstrate its association with  
15 rheumatoid arthritis, multiple sclerosis, and myocardial infarction in Swedish population.

16 Other association of this SNP with autoimmune diseases such as systemic lupus  
17 erythematosus <sup>25</sup>, myasthenia gravis <sup>26</sup>, celiac disease <sup>27</sup> and primary adrenal insufficiency <sup>28</sup>  
18 were published. However, this association is debated suggesting that gene-gene, gene-  
19 environment may interfere. As an example, a first meta-analysis found no significant  
20 association between rs3087456 and rheumatoid arthritis, whilst a significant association,  
21 further increased in Scandinavian cohorts, was identified in other study suggesting that  
22 population genetics may play an important role in rs3087456 associated clinical phenotypes  
23 <sup>29,30</sup>. Vasseur et al <sup>31</sup> provided some evidence of a positive selection of the 5' genomic region  
24 of *CIITA*. The positive selection, detected by LD-based tests and Fst tests, identified as highly

1 differentiated in Europe (27 % have a G variant, 73 % an A). In addition, SNP rs12596540 is  
2 shown to be in high linkage disequilibrium ( $r^2 > 0.6$ ) with SNP rs3087456 <sup>31</sup>.  
3 Considering the role of CIITA in the regulation of HLA-DR, and its association with  
4 immune-inflammatory diseases, we hypothesize that population-selected rs3087456 or its  
5 linked SNP rs12596540, may impact monocyte HLA-DR expression and sepsis outcome in  
6 critically septic patient, and evaluate the role of IFN- $\gamma$  in reversing the phenotype.

## 1 **MATERIALS AND METHODS**

### 2 **Study Population and Human Samples**

3 Two hundred and twenty-one DNA samples were obtained from septic shock patients  
4 admitted in the Critical Care Unit of the department of Anesthesiology, Lariboisière  
5 University Hospital, Paris, France, between February 2004 and November 2005. The study  
6 was approved by the Cochin Hospital Ethics Committee (# CCPPRB 2061), Assistance  
7 Publique Hôpitaux de Paris. Of the 221 samples, 17 had insufficient amount of DNA for SNP  
8 genotyping and one patient had no data for the primary outcome. All patients fulfilled criteria  
9 of the American College of Chest Physicians/Society of Critical Care Medicine for septic  
10 shock<sup>32</sup>. Patients were followed up throughout their ICU stay. Only subjects with clinical and  
11 biological data available for more than 7 days were analyzed. Clinical and biological  
12 characteristics were also collected. These included demographic characteristics (e.g. age,  
13 gender), biological data such as measurement of mHLA-DR on a twice weekly base, severity  
14 scores (e.g. SAPS II: Simplified Acute Physiology Score II and SOFA: Sequential Organ  
15 Failure Assessment), infection foci and complete blood cell count. For *ex-vivo* and *in-vitro*  
16 experiments, peripheral blood from healthy blood donors were collected at the French  
17 national blood collection center (*Etablissement Francais du Sang, EFS*). According to EFS  
18 standardized procedures for blood donation, written informed consent was obtained from  
19 healthy volunteers.

### 20 **SNP Genotyping**

21 Genomic DNA (gDNA) was extracted from 200 µL of peripheral whole blood using the  
22 NucleoSpin Blood kit (Macherey-Nagel, Düren, Deutschland) following manufacturer's  
23 instruction. Genomic DNA concentration was measured (NanoDrop 2000 spectrophotometer,  
24 ThermoFisher, Waltham, MA) and quality assessed (260/280 ratio between 1.7-1.9). Presence  
25 of two single nucleotide polymorphisms -286G/A (rs3087456) and -712G/A (rs12596540)



1 located on the *CHITA* promoter III were analyzed. Genotyping was performed blinded to the  
2 clinical data. SNP genotype was performed using commercially available TaqMan assays  
3 (Life Technologies, La Jolla, CA). Probe and primer combinations were designed to  
4 discriminate the two SNPs (Supplemental material, Table 1). Real time allelic discrimination  
5 assays were performed using SsoFast Probes Supermix (Bio-Rad, Hercules, CA) and a CFX-  
6 96 real time PCR system (Bio-Rad, Hercules, CA).

### 7 **Cell isolation and culture**

8 Peripheral blood mononuclear cells from healthy volunteers were isolated by Ficoll density-  
9 gradient centrifugation. B cells from blood donors were isolated using the MS columns and  
10 the CD19 Microbeads kit (Miltenyi Biotec, Bergisch Gladbach, Germany) following  
11 manufacturer's protocols. Monocytes were isolated by positive selection using MS columns  
12 and the CD14 Microbeads kit (Miltenyi Biotec, Bergisch Gladbach, Germany). To assess the  
13 cell purity by flow cytometry analysis, B cells were stained with fluorescein isothiocyanate  
14 (FITC)-conjugated anti-CD20 (Miltenyi Biotec, Bergisch Gladbach, Germany), and  
15 monocytes were labeled with phycoerythrin (PE)-conjugated anti-CD14 (BD Biosciences, Le  
16 Pont de Claix, France). Isolated cells had an average purity of 90% ( $\pm$  8%) as determined by  
17 flow cytometry analysis.

18 PBMCs were cultured in 24-well plates at  $2 \times 10^6$  cells/ml in RPMI with 10% FBS at 37°C,  
19 5% CO<sub>2</sub>. Isolated CD14<sup>+</sup> cells were cultured at  $2.5 \times 10^5$  in 24-well plates in DMEM with 5%  
20 FBS at 37°C, 5% CO<sub>2</sub>. Isolated CD19<sup>+</sup> cells were cultured at  $10^5$  cells in 96-well plates in  
21 RPMI 10% FBS at 37°C, 5% CO<sub>2</sub>. Cultured cells were incubated in the presence or absence  
22 of 50 UI/ml of human recombinant IFN- $\gamma$  (ImmunoTools, Friesoythe, Germany). After 6  
23 hours, CD14<sup>+</sup> and CD19<sup>+</sup> cells were harvested for RNA extraction, whilst after 24 hours,  
24 PBMCs were collected for FACS analysis.

### 25 **Total RNA isolation and quantitative PCR analysis**

1 Total RNA was isolated from monocytes and B cells using the NucleoSpin® RNA XS  
2 (Macherey-Nagel, Düren, Deutschland), following manufacturer's instruction. cDNA was  
3 generated from 200 ng of total RNA using iScript™ cDNA Synthesis Kit (Bio-Rad, Hercules,  
4 CA). Primers for each CIITA isoform and for the large subunit of ribosomal protein  
5 (RPLPO), were designed using the software Beacon Designer 7.0 (PREMIER Biosoft, Palo  
6 Alto, CA) and are reported in together with working concentrations and amplification  
7 efficiencies (Supplemental material, Table 1). RPLPO was used as a reference gene and the  
8 relative quantity of the transcript was calculated by the  $2^{-\Delta\Delta Ct}$  method<sup>33</sup>. PCR reactions were  
9 performed in a CFX96 real time PCR system (Bio-Rad Hercules, CA) using the SsoFast  
10 EvaGreen Supermix (Bio-Rad, Hercules, CA).

#### 11 **Flow cytometry analysis**

12 For septic patients, mHLA-DR analysis was described elsewhere<sup>34</sup>. Shortly, peripheral blood  
13 was sampled in EDTA anticoagulants tubes at different time points (day 1, 2, 7, 14, 21 and  
14 28) following admission. Quantification of mHLA-DR on circulating monocytes was  
15 performed using a standardized flow cytometry assay as previously described<sup>34,35</sup>. To  
16 quantify, the median fluorescence intensity of the entire monocyte population was then  
17 transformed to number of antibodies per cell (AB/C) using calibrated PE beads (BD  
18 QuantiBRITE™ PE BEADS, Becton-Dickinson San Jose, CA).

19 For analysis of healthy donors' blood, isolated peripheral blood mononuclear cells (PBMCs),  
20 monocytes and B cells were washed once in PBS. After being washed once in cold PBS, cells  
21 were incubated at 4°C for 15' with the Human Fc Receptor Binding Inhibitor (eBioscience,  
22 San Diego, CA) to avoid unspecific binding of labeled antibodies. Cells were then incubated  
23 with fluorescently labeled antibodies were added for 15 min at 4°C. The antibodies mix  
24 contained: Fluorescein isothiocyanate (FITC)-conjugated anti-CD20 (mouse monoclonal  
25 IgG1κ, clone LT20, Miltenyi Biotec, Bergisch Gladbach, Germany), phycoerythrin (PE)-

1 conjugated anti-CD14 (mouse monoclonal IgG2 $\alpha$ , $\kappa$ , clone M5E2, BD Biosciences, Franklin  
2 Lakes NJ) and PE-cyanine 7 (PE-Cy7)-conjugated anti-HLADR (mouse monoclonal IgG2 $\alpha$ , $\kappa$ ,  
3 clone G46-6, BD Biosciences, Franklin Lakes, NJ). After two PBS washes, cells were  
4 suspended in 1% paraformaldehyde. Flow cytometry was performed on a BD FACSCanto  
5 (BD Biosciences, Franklin Lakes, NJ) and results analyzed by the software FlowJo (TreeStar  
6 Inc, Ashland, OR).

### 7 **Cell culture and Transfection**

8 Human leukemic monocyte lymphoma cell line U937 and human Burkitt's lymphoma cells  
9 (Raji) were cultured in RPMI 1640 containing 10% heat-inactivated foetal bovine serum  
10 (FBS), 1.0 mM sodium pyruvate, amino acids, 20 mM HEPES, 100 U/ml penicillin, 100  
11  $\mu$ g/ml streptomycin at 37°C in 5% CO<sub>2</sub>. 4 x 10<sup>5</sup> cells were transfected with 1  $\mu$ g of reporter  
12 plasmid and 10 ng of pRL Renilla luciferase vector (Promega, Madison, WI) using  
13 Turbofect™ Transfection Reagent (Thermo Fisher Scientific, Fermentas, Waltham, MA).  
14 After transfection, the cells were incubated for 30 hours and stimulated by 50 UI/ml rIFN- $\gamma$   
15 (ImmunoTools, Friesoythe, Germany) for 6h or left untreated.

### 16 **Plasmid and Dual-Luciferase Reporter assays**

17 The 1200 bp of the type III promoter of MHCIIITA was cloned in pGL-3 firefly luciferase  
18 reporter vector (Promega, Madison, WI). Single-nucleotide polymorphisms G-286A  
19 (rs3087456) and G-712A (rs12596540) were inserted by using site-specific mutagenesis  
20 following published protocols. All the inserts were verified by Sanger sequencing. Dual-  
21 Luciferase assay was performed with the Dual-Glo luciferase Assay (Promega, Madison, WI),  
22 following manufacturer's instructions. Firefly and Renilla luciferase substrates fluorescence  
23 was recorded by a TriStar LB 941 (Berthold Technologies, Wilbad, Germany). As an internal  
24 control, pRL-TK, expressing the Renilla luciferase under the control of the constitutive TK  
25 promoter was co-transfected (Promega, Madison, WI). Results are represented by the mean

1 value and the standard deviation and are expressed as relative luciferase activity (ratio of  
2 firefly luciferase activity to renilla luciferase activity). To confirm the results, experiments  
3 were performed in triplicates and each one was carried out three times.

#### 4 **Statistical analysis**

5 Allele and genotype frequencies were calculated by direct counting. Hardy-Weinberg  
6 equilibrium for the two SNPs was assessed by the software Arlequin v3.11. Analysis of  
7 association between genotype and binomial clinical outcomes using different genetic models  
8 was performed by using the software plink (<http://pngu.mgh.harvard.edu/~purcell/plink/>).  
9 Results are presented as range and median for continuous variables and as proportion of total  
10 for categorical variables. Differences in HLA-DR, SOFA and SAPS II scores for the different  
11 genotypes were analyzed by using the Kruskal-Wallis test run in STATA software. The  
12 Wilcoxon rank sum test was applied to analyze continuous variables between different  
13 genotypes. Mann-Whitney Test was applied for analysis of luciferase experiments by using  
14 the software GraphPad Prism 8.0. *P* values < 0.05 were considered significant.

1 **RESULTS**

2

3 **Severity and mortality in septic shock in association to *CIITA* rs12596540 and rs3087456**

4 **genotypes**

5 Two hundred and three patients with septic shock were included in the analysis. The main  
6 patient characteristics are shown in Table 1. Allele frequency and genotype distribution were  
7 similar to that observed by Vasseur et al<sup>31</sup>: rs3087456: AA 45%, AG 41%, GG 13%;  
8 rs12596540: AA 56%, AG 37%, GG 7%. Most cell counts were not significantly different  
9 between genotypes, but patients who had the *CIITA* rs12596540 GG genotype had a higher  
10 lymphocyte count. Both polymorphisms met the Hardy Weinberg law in our cohort. To  
11 determine whether *CIITA* rs12596540 and rs3087456 SNPs were associated with severity and  
12 mortality in septic shock, genotype frequencies were determined. As reported in Table 1, no  
13 significant association was found for both SNPs with clinical severity scores (SAPS II and  
14 SOFA scores at day 1). As given in Table 2, we observed a trend of increasing mortality in  
15 patients with GG genotype for both SNPs. In an A-dominant model, patients homozygous for  
16 allele *CIITA* rs3087456 GG genotype had a significant increased risk of 28-day mortality  
17 (55.6% for GG genotype vs. 35.2% for AA and AG genotypes, OR: 2.298, CI 95% [1.013-  
18 5.217],  $P = 0.043$ ) (Table 2). The presence of rs3087456\*A allele was associated with a  
19 decreased risk of death from septic shock. We noted that there was a non-significant trend  
20 towards an increase in 7-day mortality for GG genotype for rs12596540 (AA or AG: 25.9%  
21 vs. GG: 50%, OR: 2.857, CI 95% [0.954-8,558],  $P = 0.05$ ). No association was found for  
22 secondary infections between the different genotypes of *CIITA* promoter III gene in both  
23 SNPs (Table 2**Error! Reference source not found.**). We further evaluate the impact of both  
24 SNPs on mHLA-DR expression in septic shock patients.

25

## 1 ***CIITA* rs12596540 and rs3087456 genotypes and mHLA-DR surface expression**

2 In septic shock patients, circulating mHLA-DR expression was measured at different time  
3 point during the ICU stay. For the rest of the analysis, due to the mortality data suggesting an  
4 effect only in an A-dominant model, we considered only this later model. For rs12596540 and  
5 rs3087456, septic patients with AA or AG genotype showed a significant early increase in  
6 mHLA-DR level, whereas patients with GG genotype displayed a persistent low mHLA-DR  
7 values (Wilcoxon signed rank test,  $P < 0.03$  vs. basal) (Figure 1**Error! Reference source not**  
8 **found.**).

9 To investigate the role of *CIITA* polymorphisms in healthy individuals, we measured basal  
10 mHLA-DR expression in 50 controls and evaluate its response to IFN- $\gamma$  *ex-vivo* stimulation.  
11 There was no difference between different genotypes in both polymorphisms (rs3087456: AA  
12 or AG = 1371 [95%CI, 1154 to 1625] MFI vs. GG = 1192 [95% CI, 864 to 2207] MFI,  $P =$   
13 0.87; rs12596540: AA or AG = 1374 [95%CI, 1154 to 1642] MFI vs. GG = 1137 [95%CI,  
14 864 to 1889] MFI,  $P = 0.45$ ; Figure 2). Following IFN- $\gamma$  stimulation, mHLA-DR significantly  
15 increased in monocytes of healthy volunteers with AA or AG genotype (rs3087456: 1455 vs.  
16 3569 MFI [CI 95%, 1572 to 2656],  $P < 0.0001$ ; rs12596540: 1471 vs. 3518 MFI [CI 95%,  
17 1506 to 2587],  $P < 0.0001$ ; Figure 2). For rs3087456, mHLA-DR was significantly lower for  
18 GG genotype after stimulation with IFN- $\gamma$  (AA or AG = 3919 [95%CI, 2912 to 4434] MFI vs.  
19 GG = 1898 [95% CI, 1284 to 2835] MFI,  $P < 0.05$ , Figure 2). In healthy volunteers, a  
20 homozygous GG status did not allow such a high response to IFN- $\gamma$ . As with mortality data,  
21 we did not observe significant difference in mHLA-DR expression with rs12596540  
22 genotypes and focused the rest of the analysis on rs3087456 genotype. To evaluate the effect  
23 of rs3087456 on *CIITA* expression regulation, we tested its specific activity on pIII on  
24 different leukemoid cell lines.

25

1 **Promoter activity of A/G at position -286 (rs3087456) in the type III promoter of *CIITA***

2 Functional consequence of this polymorphism on pIII activity was evaluated using reporter  
3 gene assays. To understand the mechanism by which *CIITA* gene transcripts are expressed,  
4 dual luciferase reporter assays were used to detect specific *CIITA* promoter activity. After  
5 transfection into a monocyte-like cell line (U937), G-286A\*rs3087456 pIII activity  
6 significantly decreased compared with the activity of wild-type (WT) construct ( $P < 0.001$ )  
7 (Figure 3). After stimulation by IFN- $\gamma$ , activity of G-286A\*rs3087456 pIII recovered a similar  
8 activity than WT promoter ( $P < 0.001$ ) (Figure 3). As isoforms of pIII are specific of B and  
9 activated-T cells, we transfected B lymphocyte-like cell line (Raji) and T lymphocyte-like cell  
10 line (Jurkat T). In B cells, luciferase activity of G-286A\*rs3087456 pIII significantly  
11 decreased compared with WT ( $P < 0.05$ ), and IFN- $\gamma$  did not restore activity of mutated pIII ( $P$   
12 = 0.23) (Figure 3). For T cells, activity of G-286A\*rs3087456 pIII failed to show any  
13 difference compared to WT promoter both on basal and IFN- $\gamma$  stimulated condition (Figure  
14 3). These results confirmed that *CIITA* pIII activity is involved in the decrease of mHLA-DR  
15 expression in homozygote GG healthy volunteers. To prove the transcriptional effect of G-  
16 286A\*rs3087456 pIII on *CIITA* expression, we quantified pIII related transcripts.

17

18 **Rs3087456 genotype effect on *CIITA* isoforms expression**

19 To determine whether the *CIITA* rs3087456 polymorphism was associated with different  
20 expression of *CIITA* isoforms derived from the promoter pIII and pIV, mRNA of purified  
21 monocytes (CD14<sup>+</sup>) and B cells (CD19<sup>+</sup>) was quantified by Q-PCR. mRNA encoding *CIITA*  
22 pI isoform was not recovered in isolated monocytes and B cells from healthy donors (data not  
23 shown). In monocytes, no difference in basal expression level of pIII ( $P = 0.18$ ) and pIV ( $P =$   
24 0.24) transcripts between AA or AG and GG genotypes (Figure 4). After 6 hours of *ex-vivo*  
25 cells stimulation with IFN- $\gamma$ , pIII and pIV transcripts were significantly up-regulated ( $P <$

1 0.0001, Figure 4) in monocytes for AA or AG as well as GG genotype (Figure 4). In B cells,  
2 no difference was observed in pIII or pIV transcripts expression in unstimulated cells.  
3 Following IFN- $\gamma$  stimulation, only AA or AG genotype pIV transcripts expression  
4 significantly increased ( $P < 0.05$ , Figure 4). However, pIV transcripts induction following  
5 IFN- $\gamma$  stimulation was much higher in monocytes (45 fold increase: from 1.46 [CI 95%, 0.59  
6 to 2.28] to 66.98 [CI 95%, 38.32 to 164.6]) than in B cells (2 fold increase, from 4.40 [CI  
7 95%, 2.37 to 8.27] to 8.70 (CI 95%, 4.42-12.05)) (Figure 4). Altogether rs3087456  
8 polymorphism was not impacting *CITA* isoforms basal expression, but is similarly inducible  
9 by IFN- $\gamma$  in both AA or AG and GG in monocytes but not in B cells.

10

11



## 1 **DISCUSSION**

2 In this study, we showed that G-286A *CIITA* promoter polymorphism is associated with an  
3 increase 28-day mortality in septic shock and altered mHLA-DR kinetics. Monocyte HLA-  
4 DR impaired expression is related to an altered response to IFN- $\gamma$  stimulation in G-286A. This  
5 regulatory effect seems to be related to altered basal pIII activity that is restored in G-286A  
6 after IFN- $\gamma$  stimulation.

7

8 Gene polymorphisms is widely recognized as important determinants of host response to  
9 pathogens and infections have been a strong selective sieve of human genome evolution <sup>36,37</sup>.  
10 In this respect, multiple human gene polymorphisms, positively selected in the population, are  
11 associated with survival during infection <sup>38,39</sup>. For example, premature stop codon inactivating  
12 the caspase-12 gene has been suggested to provide a selective advantage through sepsis  
13 resistance in population that experience more infectious diseases <sup>40</sup>. Nevertheless, different  
14 studies supported the idea that allele selected to resist to human pathogens, may play a role in  
15 autoimmune disease susceptibility <sup>41</sup>. Recently, Vasseur et al <sup>31</sup> identified one selected SNP of  
16 *CIITA* promoter region, rs3087456, which is positively selected in humans and known to be  
17 associated with autoimmunity, and therefore may prove to be a strong candidate SNP in  
18 sepsis resistance. In our study, rs3087456 is associated with improved survival to septic shock  
19 confirming its potential selective function. In addition to Swanberg et al <sup>23</sup> showing that  
20 rs3087456 is correlated with MHC class II transcripts, we showed its correlation with  
21 expression of HLA-DR on the cell membrane of monocytes in patients with septic shock. In  
22 homozygous GG patients, our data showed that mHLA-DR remained low throughout the ICU  
23 stay, suggesting that persistent sepsis-induced immunodepression may be partially related to  
24 this polymorphism.

25

1 The effect of the rs3087456 polymorphism on the regulation of HLA-DR expression has not  
2 been previously studied. To our knowledge, this is the first study to investigate the regulatory  
3 effects of this promoter polymorphism. Our results suggest that GG genotype alters pIII  
4 activity in monocytes and B cells but not in T cells, in a cell-type specific manner.  
5 Unexpectedly, on basal condition (e.g. monocytes and B lymphocytes from healthy  
6 volunteers), pIII related transcripts induction is not significantly different between all  
7 haplotypes. Following *ex vivo* stimulation with IFN- $\gamma$ , pIII transcripts expression was  
8 increased only in monocytes. Similarly, pIV transcripts expression is not different in the basal  
9 condition, but expression increases after IFN- $\gamma$  only in monocytes. These suggest that, in basal  
10 condition (e.g. healthy), transcriptional induction counteracts altered promoter activity of GG  
11 or repressor inhibit transcription in AA or AG haplotypes, both hypotheses encompassing  
12 complex transcription regulatory mechanisms.

13

14 Few *CIITA* transcriptional regulatory mechanisms are described. Recently, immune-  
15 enhancing CpG and non-CpG oligodeoxynucleotides (ODNs) have been described as having  
16 a role in regulating expression of MHC class II and costimulatory molecules. Wang et al <sup>42</sup>  
17 showed that non-CpG ODNs (rODNs) down-regulate HLA-DR expression in monocytes and  
18 block promoter III-directed transcription of *CIITA* in these cells. The precise inhibitory  
19 molecular effects of rODN on pIII activity are not understood, and more specifically, its  
20 precise promoter interaction not studied. Lohsen et al <sup>43</sup> described a distal regulatory  
21 elements, known as hypersensitive site 1 - HSS1 (located ~3kb upstream of pI) with PU.1,  
22 NF- $\kappa$ B, and Sp1 interacting with pIII through a looping interaction. Interestingly, proximal  
23 regulatory elements were described, and include inducers (e.g. AP-1, Sp1, CREB, NF-Y,  
24 ARE-1, ARE-2), and repressors (eg. PRDI-BF1/BLIMP-1, ZBTB32). Other mechanisms are  
25 involved in *CIITA* expression regulation. Among these, in B cells, restricted access of pI due

1 to extensive DNA methylation induces a switch to pIII activation <sup>43</sup>. The -300 region of *CIITA*  
2 has been well identified as an important proximal regulatory regions <sup>44</sup>. It is plausible that pIII  
3 rs3087456 polymorphism may interfere with transcription in monocyte during sepsis and  
4 *CIITA* expression be rescued through IFN- $\gamma$  stimulation. Whether this may be directly related  
5 to a cis- or trans- regulatory mechanism is unknown. Ni et al <sup>45</sup> identified a dependent distal  
6 enhancer regulating IFN- $\gamma$ -induce expression of *CIITA* through pIV. This IFN- $\gamma$  induce  
7 promoter activation is dependent on BRG1, an ATP-dependent remodeling factor, which  
8 promotes the formation of a dynamic three-dimensional chromatin loop and demonstrates the  
9 importance of distant enhancer/silencer regions in *CIITA* expression regulation. In our study  
10 we showed that expression in monocyte of pIV isoforms following IFN- $\gamma$  is ~2.7 fold higher  
11 than pIII, which confirms the preferential activation of pIV after IFN- $\gamma$  induction. Altogether,  
12 these facts support the evidence that IFN- $\gamma$  is a preferential inducer of *CIITA* expression that  
13 may overcome monocytic MHC class II phenotype triggered by rs3087456 polymorphism in  
14 septic patients. The detailed transcriptional mechanism is unknown but the complexity of the  
15 regulation of *CIITA* expression renders difficult the precise determination out of high-  
16 throughput promoter analysis.

17

18 Another observation of this study is the relation between *CIITA* promoter III SNP and  
19 mortality in septic shock. Outside the indirect relation between *CIITA* expression and  
20 mortality through mHLA-DR expression <sup>17,46,47</sup>, there is increasing descriptions of the direct  
21 role of *CIITA* in regulating various effectors encountered during sepsis. *CIITA* has been  
22 shown to regulate the expression of several immune related genes such as interleukin (IL)-4,  
23 collagen  $\alpha$ 2, Fas ligand, and plexin A1. As an illustration, Nozell et al <sup>48</sup> showed that *CIITA*  
24 was able to inhibit MMP-9 expression, a matrix metalloproteinase involved in the degradation  
25 of extracellular matrix in lung injury. Interestingly, the inhibition of MMP-9 in a sepsis rat

1 model with induced lung injury resulted in an increase survival <sup>49</sup>. Hereby, we show that IFN-  
2  $\gamma$  was able, in rs3087456 GG genotype, to restore *CIITA* promoter activity, CIITA pIII and  
3 pIV expression as well as HLA-DR expression in monocyte, suggesting that IFN- $\gamma$  may be a  
4 suitable immunomodulatory therapy to recover MHC class II expression. In the seminal  
5 article by Döcke et al <sup>50</sup>, authors showed that IFN- $\gamma$  was able to restore monocyte functions in  
6 8 patients with sepsis. More recently, in a cohort of 20 paediatrics and adults' patients with  
7 sepsis, we showed that immunotherapy with IFN- $\gamma$  was safe to improve the immune host  
8 defense, particularly the monocyte HLA-DR expression in patients with prolonged  
9 downregulation of mHLA-DR, and was associated with a very high survival rate <sup>51</sup>. However,  
10 Leentjens et al <sup>52</sup> suggested in healthy volunteers with LPS-induced immunoparalysis that the  
11 modulatory effect of IFN- $\gamma$  is variable, despite the significant increase in mHLA-DR  
12 expression. Interestingly, GM-CSF did not induce a significant increase in mHLA-DR in this  
13 study <sup>52</sup>. This is in agreement with the study of Hornell et al <sup>53</sup> showing that GM-CSF increase  
14 *CIITA* type I and III transcript expression but not of type IV. The use of mHLA-DR to assess  
15 the risk of secondary infection after septic shock is well admitted <sup>14,15</sup>. The use of a threshold  
16 of 8,000 AB/C to define a reduction in mHLA-DR expression to diagnose an acquired  
17 immunosuppression gets more credence, in particular if it is lasting after day 3 post admission  
18 <sup>51,54</sup>. Hereby, we showed that rs3087456 GG genotype was significantly associated with  
19 unresolving low mHLA-DR kinetics, predicting a persistent immunodepression phenotype in  
20 patients with septic shock.

21

22 This study opens two important perspectives: First, a genetic susceptibility affecting MHC  
23 class II master regulator *CIITA* is shown to be associated with defective mHLA-DR  
24 expression in patients with septic shock and dismal outcome. This allows to anticipate the  
25 development of sepsis-induced immunodepression. Second, the demonstration of IFN- $\gamma$  effect

- 1 to rescue the functional consequence of this genotype, suggest the use of this genetic
- 2 biomarker to identify patients who may benefit of IFN- $\gamma$ -based immunomodulatory therapy.
- 3 In conclusion, we report that *CIITA* rs3087456 GG genotype is associated with impaired m-
- 4 HLA-DR expression in septic shock, predictive of development of persistent
- 5 immunodepression, and demonstrate the effect of IFN- $\gamma$  to rescue altered MHC class II
- 6 expression.

## 1   **REFERENCES**

- 2   1. Reinhart, K. *et al.* Recognizing Sepsis as a Global Health Priority — A WHO Resolution.  
3       *N. Engl. J. Med.* 377, 414–417 (2017).
- 4   2. Fleischmann, C. *et al.* Assessment of Global Incidence and Mortality of Hospital-treated  
5       Sepsis. Current Estimates and Limitations. *Am. J. Respir. Crit. Care Med.* 193, 259–272  
6       (2016).
- 7   3. Kumar, G. *et al.* Nationwide trends of severe sepsis in the 21st century (2000-2007).  
8       *Chest* 140, 1223–1231 (2011).
- 9   4. Rhodes, A. *et al.* Surviving Sepsis Campaign: International Guidelines for Management  
10       of Sepsis and Septic Shock: 2016. *Intensive Care Med.* 43, 304–377 (2017).
- 11   5. Singer, M. *et al.* The Third International Consensus Definitions for Sepsis and Septic  
12       Shock (Sepsis-3). *JAMA* 315, 801–810 (2016).
- 13   6. Hotchkiss, R. S., Monneret, G. & Payen, D. Sepsis-induced immunosuppression: from  
14       cellular dysfunctions to immunotherapy. *Nat. Rev. Immunol.* 13, 862–874 (2013).
- 15   7. Ziegler, E. J. *et al.* Treatment of gram-negative bacteremia and shock with human  
16       antiserum to a mutant *Escherichia coli*. *N Engl J Med* 307, 1225–30 (1982).
- 17   8. Eichacker, P. Q. *et al.* Risk and the efficacy of antiinflammatory agents: retrospective and  
18       confirmatory studies of sepsis. *Am J Respir Crit Care Med* 166, 1197–205 (2002).
- 19   9. Minneci, P. C., Deans, K. J., Eichacker, P. Q. & Natanson, C. The effects of steroids  
20       during sepsis depend on dose and severity of illness: an updated meta-analysis. *Clin*  
21       *Microbiol Infect* 15, 308–18 (2009).
- 22   10. Shakoory, B. *et al.* Interleukin-1 Receptor Blockade Is Associated With Reduced  
23       Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome:  
24       Reanalysis of a Prior Phase III Trial. *Crit. Care Med.* 44, 275–281 (2016).

- 1 11. Abraham, E. *et al.* Drotrecogin alfa (activated) for adults with severe sepsis and a low risk  
2 of death. *N Engl J Med* 353, 1332–41 (2005).
- 3 12. Warren, H. S., Suffredini, A. F., Eichacker, P. Q. & Munford, R. S. Risks and benefits of  
4 activated protein C treatment for severe sepsis. *N Engl J Med* 347, 1027–30 (2002).
- 5 13. Suffredini, A. F. & Munford, R. S. Novel therapies for septic shock over the past 4  
6 decades. *Jama* 306, 194–9 (2011).
- 7 14. Lukaszewicz, A. C., Faivre, V. & Payen, D. Is monocyte HLA-DR expression monitoring  
8 a useful tool to predict the risk of secondary infection? *Minerva Anesthesiol* 76, 737–43  
9 (2010).
- 10 15. Wu, J. F. *et al.* Changes of monocyte human leukocyte antigen-DR expression as a  
11 reliable predictor of mortality in severe sepsis. *Crit Care* 15, R220 (2011).
- 12 16. Monneret, G., Lepape, A. & Venet, F. A dynamic view of mHLA-DR expression in  
13 management of severe septic patients. *Crit. Care Lond. Engl.* 15, 198 (2011).
- 14 17. Pachot, A. *et al.* Messenger RNA expression of major histocompatibility complex class II  
15 genes in whole blood from septic shock patients. *Crit Care Med* 33, 31–8; discussion 236-  
16 7 (2005).
- 17 18. Cajander, S. *et al.* Quantitative Real-Time Polymerase Chain Reaction Measurement of  
18 HLA-DRA Gene Expression in Whole Blood Is Highly Reproducible and Shows Changes  
19 That Reflect Dynamic Shifts in Monocyte Surface HLA-DR Expression during the  
20 Course of Sepsis. *PLOS ONE* 11, e0154690 (2016).
- 21 19. Peronnet, E. *et al.* Association between mRNA expression of CD74 and IL10 and risk of  
22 ICU-acquired infections: a multicenter cohort study. *Intensive Care Med.* 43, 1013–1020  
23 (2017).
- 24 20. Reith, W., LeibundGut-Landmann, S. & Waldburger, J. M. Regulation of MHC class II  
25 gene expression by the class II transactivator. *Nat Rev Immunol* 5, 793–806 (2005).

- 1 21. Mach, B., Steimle, V. & Reith, W. MHC class II-deficient combined immunodeficiency:  
2 a disease of gene regulation. *Immunol Rev* 138, 207–21 (1994).
- 3 22. Steimle, V., Otten, L. A., Zufferey, M. & Mach, B. Complementation cloning of an MHC  
4 class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte  
5 syndrome). 1993. *J Immunol* 178, 6677–88 (2007).
- 6 23. Swanberg, M. *et al.* MHC2TA is associated with differential MHC molecule expression  
7 and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction.  
8 *Nat Genet* 37, 486–94 (2005).
- 9 24. Xue, Y. *et al.* Link between CIITA rs3087456 polymorphism and the risk of laryngeal  
10 squamous cell carcinoma in a Chinese population. *Pathol. Res. Pract.* 216, 152793  
11 (2020).
- 12 25. Bronson, P. G. *et al.* The rs4774 CIITA missense variant is associated with risk of  
13 systemic lupus erythematosus. *Genes Immun* 12, 667–71 (2011).
- 14 26. Ramanujam, R., Zhao, Y., Pirskanen, R. & Hammarström, L. Lack of association of the  
15 CIITA -168A→G promoter SNP with myasthenia gravis and its role in autoimmunity.  
16 *BMC Med. Genet.* 11, 147 (2010).
- 17 27. Dema, B. *et al.* Autoimmune disease association signals in CIITA and KIAA0350 are not  
18 involved in celiac disease susceptibility. *Tissue Antigens* 73, 326–329 (2009).
- 19 28. Skinningsrud, B. *et al.* Polymorphisms in CLEC16A and CIITA at 16p13 are associated  
20 with primary adrenal insufficiency. *J. Clin. Endocrinol. Metab.* 93, 3310–3317 (2008).
- 21 29. Bronson, P. G., Criswell, L. A. & Barcellos, L. F. The MHC2TA -168A/G polymorphism  
22 and risk for rheumatoid arthritis: a meta-analysis of 6861 patients and 9270 controls  
23 reveals no evidence for association. *Ann Rheum Dis* 67, 933–6 (2008).
- 24 30. Eike, M. C. *et al.* CIITA gene variants are associated with rheumatoid arthritis in  
25 Scandinavian populations. *Genes Immun* 13, 431–6 (2012).



- 1 31. Vasseur, E. *et al.* The evolutionary landscape of cytosolic microbial sensors in humans.  
2 *Am J Hum Genet* 91, 27–37 (2012).
- 3 32. Levy, M. M. *et al.* 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions  
4 Conference. *Crit Care Med* 31, 1250–6 (2003).
- 5 33. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time  
6 quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods San Diego Calif* 25,  
7 402–408 (2001).
- 8 34. Lukaszewicz, A. C. *et al.* Monocytic HLA-DR expression in intensive care patients:  
9 interest for prognosis and secondary infection prediction. *Crit Care Med* 37, 2746–52  
10 (2009).
- 11 35. Demaret, J. *et al.* Inter-laboratory assessment of flow cytometric monocyte HLA-DR  
12 expression in clinical samples. *Cytometry B Clin. Cytom.* 84B, 59–62 (2013).
- 13 36. Quintana-Murci, L., Alcaïs, A., Abel, L. & Casanova, J.-L. Immunology in natura □:  
14 clinical, epidemiological and evolutionary genetics of infectious diseases. *Nat. Immunol.*  
15 8, 1165–1171 (2007).
- 16 37. Casanova, J.-L. & Abel, L. The human genetic determinism of life-threatening infectious  
17 diseases: genetic heterogeneity and physiological homogeneity? *Hum. Genet.* 139, 681–  
18 694 (2020).
- 19 38. Deschamps, M. *et al.* Genomic Signatures of Selective Pressures and Introgression from  
20 Archaic Hominins at Human Innate Immunity Genes. *Am. J. Hum. Genet.* 98, 5–21  
21 (2016).
- 22 39. Quintana-Murci, L. Human Immunology through the Lens of Evolutionary Genetics. *Cell*  
23 177, 184–199 (2019).
- 24 40. Xue, Y. *et al.* Spread of an inactive form of caspase-12 in humans is due to recent positive  
25 selection. *Am J Hum Genet* 78, 659–70 (2006).

- 1 41. Barreiro, L. B. & Quintana-Murci, L. From evolutionary genetics to human immunology:  
2 how selection shapes host defence genes. *Nat Rev Genet* 11, 17–30 (2010).
- 3 42. Wang, J., Roderiquez, G., Jones, T., McPhie, P. & Norcross, M. A. Control of in vitro  
4 immune responses by regulatory oligodeoxynucleotides through inhibition of pIII  
5 promoter directed expression of MHC class II transactivator in human primary  
6 monocytes. *J. Immunol. Baltim. Md 1950* 179, 45–52 (2007).
- 7 43. Lohsen, S. *et al.* Common distal elements orchestrate CIITA isoform-specific expression  
8 in multiple cell types. *Genes Immun.* 15, 543–555 (2014).
- 9 44. Ghosh, N. *et al.* A Novel Element and a TEF-2-like Element Activate the Major  
10 Histocompatibility Complex Class II Transactivator in B-lymphocytes. *J. Biol. Chem.*  
11 274, 32342–32350 (1999).
- 12 45. Ni, Z., Abou El Hassan, M., Xu, Z., Yu, T. & Bremner, R. The chromatin-remodeling  
13 enzyme BRG1 coordinates CIITA induction through many interdependent distal  
14 enhancers. *Nat Immunol* 9, 785–93 (2008).
- 15 46. Cazalis, M.-A. *et al.* Decreased HLA-DR antigen-associated invariant chain (CD74)  
16 mRNA expression predicts mortality after septic shock. *Crit. Care* 17, R287 (2013).
- 17 47. Turrel-Davin, F. *et al.* mRNA-based approach to monitor recombinant gamma-interferon  
18 restoration of LPS-induced endotoxin tolerance. *Crit. Care* 15, R252 (2011).
- 19 48. Nozell, S., Ma, Z., Wilson, C., Shah, R. & Benveniste, E. N. Class II major  
20 histocompatibility complex transactivator (CIITA) inhibits matrix metalloproteinase-9  
21 gene expression. *J Biol Chem* 279, 38577–89 (2004).
- 22 49. Steinberg, J. *et al.* Metalloproteinase inhibition reduces lung injury and improves survival  
23 after cecal ligation and puncture in rats. *J Surg Res* 111, 185–95 (2003).
- 24 50. Döcke, W. D. *et al.* Monocyte deactivation in septic patients: restoration by IFN-gamma  
25 treatment. *Nat. Med.* 3, 678–681 (1997).

- 1 51. Payen, D. *et al.* Multicentric experience with interferon gamma therapy in sepsis induced  
2 immunosuppression. A case series. *BMC Infect. Dis.* 19, 931 (2019).
- 3 52. Leentjens, J. *et al.* Reversal of immunoparalysis in humans in vivo: a double-blind,  
4 placebo-controlled, randomized pilot study. *Am. J. Respir. Crit. Care Med.* 186, 838–845  
5 (2012).
- 6 53. Hornell, T. M. C., Beresford, G. W., Bushey, A., Boss, J. M. & Mellins, E. D. Regulation  
7 of the class II MHC pathway in primary human monocytes by granulocyte-macrophage  
8 colony-stimulating factor. *J. Immunol. Baltim. Md 1950* 171, 2374–2383 (2003).
- 9 54. Monneret, G. *et al.* Persisting low monocyte human leukocyte antigen-DR expression  
10 predicts mortality in septic shock. *Intensive Care Med.* 32, 1175–1183 (2006).
- 11

1 **Acknowledgments**

2 We thank Sergio Crovella (Department of Advanced Diagnostics, Institute for Maternal and  
3 Child Health-IRCCS 'Burlo Garofolo', Trieste, Italy and Department of Medical, Surgical and  
4 Health Sciences, University of Trieste, Trieste, Italy) for help with paper revisions.

5

6 **Disclosure:** All authors declare having no financial interest related to the study

7 **Contribution:**

8 ACL, DP enrolled the patients and collected clinical data

9 JM, MB, SH, KM, CB, VF performed experiments;

10 JM, MB, PT analyzed results and made the figures;

11 JM, MB, PT, DP, ACL designed the research;

12 JM, PT, MB wrote the paper;

13 All authors critically reviewed the manuscript.

14

15 **Correspondence:** Pierre Tissières, MD, DSc, Institute of Integrative Biology of the Cell.

16 CNRS-CEA-Paris-Saclay University, 1, Avenue de la Terrasse, 91190 Gif-sur-Yvette,

17 France; e-mail: pierre.tissieres@i2bc.paris-saclay.fr

1 **Tables legends**

2

3 **Table 1. Baseline characteristics of patients in septic shock.**

4 SAPS II: Simplified Acute Physiology Score II; SOFA = Sequential Organ Failure

5 Assessment. Data are median (interquartile range) for continuous variable. \* P values were

6 calculated with the use of chi-square test and Kruskal-Wallis test.

7

8 **Table 2. Genotyped related mortality.**

9 \* P values were calculated with the use of chi-square test and Kruskal-Wallis test.

1 **Figures legends**

2

3 **Figure 1. Monocyte HLA-DR expression in 203 patients with septic shock.**

4 Circulating monocyte HLA-DR expression is expressed as number of antibodies bound per  
5 cell (AB/C) as defined using calibrated PE beads (BD QuantiBRITE™ PE BEADS, Becton-  
6 Dickinson San Jose, CA). Results are presented as median with 95% CI and by genotype of  
7 CIITA rs12596540 and rs3087456 in a dominant model. \* P < 0.03 vs. basal (Wilcoxon  
8 signed rank test).

9

10 **Figure 2. HLA-DR expression in PBMCs of healthy volunteers.**

11 Mean fluorescence intensity (MFI) are presented as median with 95% CI and by genotype of  
12 CIITA rs12596540 and rs3087456 in a dominant model. P values were calculated using  
13 Mann-Whitney Test. \* P < 0.05.

14

15 **Figure 3. Transient transfection of U937, Raji and Jurkat T cells with CIITA-promoter-  
16 luciferase plasmid.**

17 Transfected cells were stimulated during 6h with IFN- $\gamma$ . CIITA promoter III activity is  
18 represented by luciferase activity over empty vector. WT = Wild Type. P values were  
19 calculated using Mann-Whitney Test. \*\*\* P < 0.001 and \* P < 0.05.

20

21 **Figure 4. mRNA levels for promoter III (pIII) and promoter IV (pIV) isoforms.**

22 mRNA level in CD14<sup>+</sup> (monocytes) and CD19<sup>+</sup> (lymphocytes) from healthy volunteers. Cells  
23 were stimulated or not by IFN- $\gamma$  during 6h before qPCR. Results are presented as median fold  
24 change relative to an AA subject normalized to HuRPLP0, and by genotype of CIITA  
25 rs3087456 in an A-dominant model. P values were calculated using Mann-Whitney Test.  
26 \*\*\*\* P < 0.0001, \*\*\* P < 0.001 and \* P < 0.05.

Figure 1.




Figure 2.






Figure 3.





Figure 4.



Tables

Table 1.

	G-712A (rs12596540)					G-286A (rs3087456)				
	AA (n = 113)	AG (n = 76)	GG (n = 14)	All (n = 203)	P Value *	AA (n = 92)	AG (n = 84)	GG (n = 27)	All (n = 203)	P Value *
Age, years	62 (18-91)	59 (19-94)	58 (33-88)	61 (18-94)	0.73	62 (18-91)	60 (19-94)	63 (30-88)	61 (18-94)	0.25
Gender, % male	66.4	63.2	64.3	65	0.90	68.5	59.5	70.4	65	0.38
SAPS II	48 (22-120)	50 (15-96)	44 (19-65)	49 (15-120)	0.58	49 (22-120)	49 (15-96)	45 (19-93)	49 (15-120)	0.44
SOFA	7 (2-15)	7 (2-16)	7 (1-11)	7 (1-16)	0.91	7 (2-15)	7 (2-16)	7 (1-16)	7 (1-16)	0.87
Surgical, %	21.2	26.3	28.6	23.6	0.65	22.8	25	22.2	23.6	0.93
<b>Sepsis origin, %</b>										
Lung	56.7	47.4	64.3	53.7	0.36	54.3	50	59.3	53.7	0.67
Abdomen	20.4	21.1	21.4	20.7	0.99	20.7	22.6	14.8	20.7	0.68
Urinary	3.5	5.3	7.1	4.4	0.75	4.3	4.8	3.7	4.4	0.97
<b>Laboratory variables</b>										
Leucocyte count, x 10 <sup>3</sup> /mm <sup>3</sup>	10.7 (0.1-55)	12.3 (0.1-92.5)	15.8 (1.8-32.7)	11.4 (0.1-92.5)	0.42	11.4 (0.1-55)	12.4 (0.1-92.5)	9.1 (0.4-32.7)	11.4 (0.1-92.5)	0.76
Neutrophil count, x 10 <sup>3</sup> /mm <sup>3</sup>	9.3 (0.1-46.2)	10.4 (0.1-74.9)	9.7 (1-28.4)	9.1 (0.1-74.9)	0.84	10.1 (0.1-46.2)	10.4 (0.1-74.9)	8.4 (0.5-29.3)	9.1 (0.1-74.9)	0.56
Lymphocyte count, x 10 <sup>3</sup> /mm <sup>3</sup>	0.6 (0.1-11.9)	0.7 (0.1-3.7)	1.7 (0.2-2.5)	0.7 (0.1-11.9)	0.005	0.7 (0.1-11.9)	0.6 (0.1-5.8)	0.9 (0.2-2.5)	0.7 (0.1-11.9)	0.17
Monocyte count, x 10 <sup>3</sup> /mm <sup>3</sup>	0.5 (0.1-2.9)	0.6 (0.1-4.6)	0.9 (0.1-7.9)	0.6 (0.1-7.9)	0.24	0.5 (0.1-2.7)	0.6 (0.1-4.6)	0.5 (0.1-7.9)	0.6 (0.1-7.9)	0.87

**Table 2.**

**Co-dominant model**

	<b>G-712A (rs12596540)</b>					<b>G-286A (rs3087456)</b>				
	<b>AA (n = 113)</b>	<b>AG (n = 76)</b>	<b>GG (n = 14)</b>	<b>All (n = 203)</b>	<b>P Value *</b>	<b>AA (n = 92)</b>	<b>AG (n = 84)</b>	<b>GG (n = 27)</b>	<b>All (n = 203)</b>	<b>P Value *</b>
<b>28-d mortality, n (%)</b>	45 (39.8)	24 (31.6)	8 (57.1)	77 (37.9)	0.16	35 (38)	27 (32.1)	15 (55.6)	77 (37.9)	0.10
<b>7-d mortality, n (%)</b>	31 (27.2)	18 (23.7)	7 (50)	56 (27.6)	0.13	25 (27.2)	21 (25)	10 (37)	56 (27.6)	0.47
<b>Secondary infections, n (%)</b>	23 (20.3)	18 (23.7)	2 (14.3)	43 (21.2)	0.70	19 (20.7)	20 (23.8)	4 (14.8)	43 (21.2)	0.61

**A-dominant model**

	<b>G-712A (rs12596540)</b>					<b>G-286A (rs3087456)</b>				
	<b>AA or AG (n = 189)</b>	<b>GG (n = 14)</b>	<b>OR</b>	<b>95% CI</b>	<b>P Value *</b>	<b>AA or AG (n = 189)</b>	<b>GG (n = 27)</b>	<b>OR</b>	<b>95% CI</b>	<b>P Value *</b>
<b>28-d mortality, n (%)</b>	69 (36.5)	8 (57.1)	2.319	0.773-6.960	0.13	62 (35.2)	15 (55.6)	2.298	1.013-5.217	0.043
<b>7-d mortality, n (%)</b>	49 (25.9)	7 (50)	2.857	0.954-8.558	0.05	46 (50)	10 (37)	1.662	0.710-3.891	0.24
<b>Secondary infections, n (%)</b>	41 (21.7)	2 (14.3)	0.602	0.129-2.796	0.49	39 (20.7)	4 (14.8)	0.611	0.199-1.872	0.38